Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Zometa approved in Canada for treatment of tumor-induced hypercalcemia

Aug. 31, 2000

BioTime seeks European approval of Hextend

Aug. 31, 2000

Alendronate markedly reduces fracture risk in women with osteoporosis

Aug. 31, 2000

AstraZeneca's rosuvastatin causes rapid reductions in LDL cholesterol

Aug. 30, 2000

Ezetimibe inhibits cholesterol absorption; tissue localization explored

Aug. 30, 2000

Schering AG's Yasmin receives European-wide approval

Aug. 30, 2000

Actonel approved in Canada

Aug. 29, 2000

New compounds under study at Merck useful for dyslipidemias, etc.

Aug. 29, 2000

Novel potent and selective beta3-adrenergic receptor agonists described

Aug. 29, 2000

Neurotransmitter inhibits food intake in rats

Aug. 29, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...